New antiviral therapies in the management of HCV infection

被引:22
作者
Farnik, Harald [1 ]
Zeuzem, Stefan [1 ]
机构
[1] Klinikum JW Goethe Univ, Med Klin 1, Frankfurt, Germany
关键词
HEPATITIS-C-VIRUS; TREATMENT-NAIVE PATIENTS; SUSTAINED VIROLOGICAL RESPONSE; NS3 PROTEASE INHIBITOR; PEGYLATED INTERFERON-ALPHA; GENOTYPE; POLYMERASE INHIBITOR; PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2A; NS5A INHIBITOR;
D O I
10.3851/IMP2127
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Improved knowledge of the HCV life cycle and of structural features of HCV proteins have led to the discovery of numerous potential targets for antiviral therapy. Viral replication and polyprotein processing have been tagged as promising viral targets. Clathrin-mediated endocytosis, fusion of HCV with cellular membranes, translation of viral RNA, virus production and release as well as several host cell factors may provide alternative targets for future anti-HCV therapies. Several compounds are currently under investigation in clinical trials and showed high antiviral activity in patients with chronic hepatitis C. Recently, Phase III studies for two protease inhibitors, telaprevir and boceprevir, each given in combination with pegylated interferon (standard of care [SOC]), were completed. In HCV-genotype-1-infected patients, the addition of telaprevir or boceprevir to SOC increased sustained virological response rates from <50% to >70%. Nucleoside/nucleotide inhibitors of the HCV NS5B polymerase have shown antiviral activity against different HCV genotypes, and have a higher barrier to resistance than protease inhibitors. In addition, several allosteric binding sites have been identified for non-nucleoside inhibitors of the NS5B polymerase. Inhibitors of NS5A are potentially active against all HCV genotypes. Among the different host cell-targeting compounds, cyclophilin inhibitors have shown promising results. Future hope lies in the combination of direct-acting antiviral agents with the possibility of interferon-free treatment regimens.
引用
收藏
页码:771 / 783
页数:13
相关论文
共 88 条
[41]  
Larrey D, 2012, J HEPATOL IN PRESS
[42]   A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION [J].
Lawitz, E. ;
Jacobson, I. ;
Godofsky, E. ;
Foster, G. R. ;
Flisiak, R. ;
Bennett, M. ;
Ryan, M. ;
Hinkle, J. ;
Simpson, J. ;
McHutchison, J. ;
Oldach, D. .
JOURNAL OF HEPATOLOGY, 2011, 54 :S181-S181
[43]   ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA &lt;LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY) [J].
Lawitz, E. ;
Rodriguez-Torres, M. ;
Denning, J. ;
Cornpropst, M. ;
Clemons, D. ;
Mcnair, L. ;
Berrey, M. M. ;
Symonds, W. .
JOURNAL OF HEPATOLOGY, 2011, 54 :S543-S543
[44]   SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION [J].
Lawitz, E. ;
Cooper, C. ;
Rodriguez-Torres, M. ;
Ghalib, K. ;
Lalonde, R. ;
Sheikh, A. ;
Bourgault, B. ;
Chauret, N. ;
Proulx, L. ;
McHutchison, J. .
JOURNAL OF HEPATOLOGY, 2009, 50 :S37-S37
[45]  
Lawitz E, 2010, HEPATOLOGY, V52, p334A
[46]   Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line [J].
Lohmann, V ;
Körner, F ;
Koch, JO ;
Herian, U ;
Theilmann, L ;
Bartenschlager, R .
SCIENCE, 1999, 285 (5424) :110-113
[47]   Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1 [J].
Lok, Anna S. ;
Gardiner, David F. ;
Lawitz, Eric ;
Martorell, Claudia ;
Everson, Gregory T. ;
Ghalib, Reem ;
Reindollar, Robert ;
Rustgi, Vinod ;
McPhee, Fiona ;
Wind-Rotolo, Megan ;
Persson, Anna ;
Zhu, Kurt ;
Dimitrova, Dessislava I. ;
Eley, Timothy ;
Guo, Tong ;
Grasela, Dennis M. ;
Pasquinelli, Claudio .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (03) :216-224
[48]   Q2WEEK CONTROLLED-RELEASE-INTERFERON-ALPHA2B+RIBAVRIN REDUCES FLU-LIKE SYMPTOMS &gt;50% AND PROVIDES EQUIVALENT EFFICACY IN COMPARISON TO WEEKLY PEGYLATED-INTERFERON-ALPHA2B+RIBAVIRIN IN TREATMENT-NAIVE-GENOTYPE-1-CHRONIC-HEPATITIS-C: RESULTS FROM EMPOWER, A RANDOMIZED-OPEN-LABEL-12-WEEK-COMPARISON IN 133 PATIENTS [J].
Long, W. A. ;
Takov, D. ;
Tchernev, K. ;
Kotzev, I. ;
Rigney, A. ;
Krastev, Z. ;
Stoynov, S. ;
Balabanska, R. ;
Lawitz, E. ;
Younossi, Z. ;
Ghalib, R. ;
Zuckerman, E. ;
Safadi, R. ;
Tur-Kaspa, R. ;
Assy, N. ;
Lurie, Y. .
JOURNAL OF HEPATOLOGY, 2010, 52 :S467-S467
[49]   Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection [J].
Manns, Michael P. ;
Bourliere, Marc ;
Benhamou, Yves ;
Pol, Stanislas ;
Bonacini, Maurizio ;
Trepo, Christian ;
Wright, David ;
Berg, Thomas ;
Calleja, Jose L. ;
White, Peter W. ;
Stern, Jerry O. ;
Steinmann, Gerhard ;
Yong, Chan-Loi ;
Kukolj, George ;
Scherer, Joe ;
Boecher, Wulf O. .
JOURNAL OF HEPATOLOGY, 2011, 54 (06) :1114-1122
[50]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965